Madrigal Pharmaceuticals (MDGL) Net Cash Flow (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Net Cash Flow data on file, last reported at $27.1 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $27.1 million, down 67.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.2 million (up 109.73% YoY), and the FY2025 annual result was $98.8 million, up 1834.78% from the prior year.
• Net Cash Flow grew to $27.1 million in Q1 2026 per MDGL's latest filing, from -$96.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $522.6 million in Q1 2024 and troughed at -$261.9 million in Q3 2024.
• A 5-year average of $11.4 million and a median of $6.0 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow surged 2209.33% in 2022, then plunged 3729.49% in 2023.
• A 5-year view of Net Cash Flow shows it stood at $272.2 million in 2022, then plunged by 86.09% to $37.9 million in 2023, then slumped by 450.41% to -$132.7 million in 2024, then advanced by 26.94% to -$96.9 million in 2025, then surged by 127.94% to $27.1 million in 2026.
• Business Quant data shows MDGL's Net Cash Flow at $27.1 million in Q1 2026, -$96.9 million in Q4 2025, and $109.5 million in Q3 2025.